Ofatumumab - Arzerra

Ofatumumab (Arzerra®), which received FDA approval on 19 January 2016, is used in advanced or relapsed chronic lymphocytic leukemiaas extended therapy in patients who have achieved a partial or complete response to their treatment. Like obinutuzumab, Ofatumumab exerts its effect through CD 20 molecules on B cells. Ofatumumab binding to CD 20 can act directly to kill the cancer cell and can also use the destructive power of the system called complement.

The most common side effects include decreased white blood cells (neuropenia), pneumonia, high fever, cough, diarrhea and anemia.